By
AmyT on
January 20, 2010
I know, I know, I had the same reaction: What the heck?! Just on the heels of the Juvenile Diabetes Research Foundation (JDRF)’s big artificial pancreas announcement last week that brings the non-profit into a commercial partnership with J&J, yesterday they released news of a new commercial partnership with Becton Dickinson (BD). The goal of this collaboration is to improve insulin pump therapy.
I found the press release a bit confusing. The wording seemed to…
Read more »
By
AmyT on
January 19, 2010
Last week, I spent a little bit of time at the JP Morgan Healthcare Conference, a nearly-thirty-year-old annual gathering that’s become “the health care industry’s premier financial event, giving more than 330 companies a chance to make formal pitches to institutional investors.” Due to a houseful of sickies at home, I wasn’t able to attend as many presentations as I’d have liked, but I did catch a few of the “biggies,” including the talk by…
Read more »
By
AmyT on
January 13, 2010
Very big news in the diabetes world today, Folks: the Juvenile Diabetes Research Foundation (JDRF) has announced a partnership with insulin pump makers Animas Corp. (a Johnson & Johnson company) to actually start building the first ready-for-market artificial pancreas, i.e. “a fully automated system to dispense insulin … based on real-time changes in blood sugar levels.” DexCom will provide the continuous glucose monitoring (CGM) technology for the new system being developed.
I was fortunate to…
Read more »
By
AmyT on
January 6, 2010
What went through your mind when you heard about the sudden death of Johnson & Johnson heiress Casey Johnson a few days ago? I can’t imagine a Type 1 diabetic out there who isn’t shuddering in their shoes. She was only 30 years old, for goodness’ sake, and despite the drugs and alcohol, she’d likely be alive today if her diabetes hadn’t played some role.
There’s been a ton of speculation since Casey, a prominent…
Read more »
By
AmyT on
January 5, 2010
At the end of last year (so, basically, two weeks ago), the Juvenile Diabetes Research Foundation announced a joint partnership with the Johnson & Johnson Corporate Office of Science and Technology to help with the discovery and development of drugs to promote beta cell survival. The program will look to fund research at academic centers around the world that could eventually lead to novel new drugs for the prevention and treatment of type 1 diabetes.
Sounds…
Read more »
